Activity Overview
This online, on-demand virtual symposium brings together renowned experts in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer. In this educational program, these experts use case-based discussions to explore real-world scenarios across the HR+/HER2– breast cancer continuum—from genomic risk stratification and adjuvant therapy selection in early-stage disease to the selection and sequencing of targeted therapies in advanced/metastatic disease.
This educational activity is an archive of the live symposium held on November 2, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, advanced practice providers, nurses, and other health care providers involved in the treatment and management of HR+/HER2– breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe key distinctions between available genomic risk assays to determine appropriate indications for use
- Apply evidence-based approaches to risk stratification in early-stage HR+/HER2– breast cancer to guide individualized adjuvant therapy decisions

Virginia Kaklamani, MD, DSc
Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Medical Director, Breast Oncology Program
UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX
Disclosures: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Daiichi Sankyo, Genentech, Gilead, Lilly, Menarini, Novartis, Pfizer; Speakers Bureau: AstraZeneca, Gilead

Marcela Mazo Canola, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Breast Oncology
UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Eli Lilly and Company, Exact Sciences, Menarini Group; Speakers Bureau: AstraZeneca, Celcuity, Gilead Sciences, Menarini Group, Rigel; Grant/Research Funding: American Cancer Society, Institute of Inherited Oncogenesis UT Health

Jessica Treviño Jones, MD
Director, Cancer Genetics
Director, CaRE Program, Cancer Risk Reduction and Education
UT Health San Antonio MD Anderson Cancer Center
Associate Professor
Division of Hematology-Oncology
UT Health San Antonio Long School of Medicine
San Antonio, TX
Disclosures: Jessica Treviño Jones, MD, has no relevant financial relationships with ineligible companies to disclose.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here